Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Which index fund performed best this year? Review top performers, volatility, and potential shifts to inform your next move.
26,831 articlesA trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Rivian’s shares fell roughly 5% after unveiling the R2, erasing prior gains as the market assesses the mass-market pr...
Mercer International posts a brutal Q4 hit from impairment, eroding equity, while International Paper pivots to highe...
Crypto markets tank $100B in a single session as the Federal Reserve signals a hawkish stance and likely fewer rate c...
Cursor, valued near $29 billion, stands at the center of a fast-moving AI coding boom. The company faces intense grow...
NVIDIA’s shares hover near $198 as investors weigh whether the AI leader’s growth justifies a premium. The stock now ...
A corporate treasury model pivots back to Bitcoin buying after a pause, adopting a clear buy-for-sell rule. This appr...
Teva has climbed more than 100% in the last year, and analysts remain cautiously optimistic. Here’s why wall street t...
KeyBanc boosts Okta's target to $103 from $95, citing a brighter security spending outlook and the central role of id...
Speculative AI-driven forecasts tied to Sam Altman's tools predict altman chatgpt predicts incredible upside for DOGE...
Investors eye SpaceX's potential IPO as the space economy broadens; public peers already provide exposure across laun...
Investors are buzzing about SpaceX and a potential IPO that could push the company toward a $2 trillion valuation. Th...